5V
5AM Venture Management, LLC
13F filer · CIK 0001799883Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$288MU.S. long equity reported on 13F
Positions160 new · 4 closed
Net flow last quarter-$110MBuys minus sells
Top 10 positions weight85.6%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202616 positions | |||||
| $34M | 11.83% | 2.09% | Not reported | Q4 2025 | |
| $32.9M | 11.42% | 1.73% | Not reported | Q3 2023 | |
| $29.9M | 10.37% | 10.42% | Not reported | Q4 2021 | |
| $27.6M | 9.58% | 1.22% | Not reported | Q2 2022 | |
| $25.6M | 8.91% | 11.30% | Not reported | Q4 2024 | |
| $22.8M | 7.93% | 9.52% | Not reported | Q3 2024 | |
| $20.9M | 7.24% | 3.15% | Not reported | Q2 2024 | |
| $19.1M | 6.65% | 5.51% | Not reported | Q2 2023 | |
| $18.5M | 6.43% | 0.63% | Not reported | Q2 2023 | |
| $15M | 5.22% | 1.24% | Not reported | Q2 2024 | |
| $11M | 3.82% | 0.49% | Not reported | Q4 2023 | |
| $7.04M | 2.44% | 2.31% | -30.0% | Q1 2025 | |
| $6.71M | 2.33% | 27.55% | Not reported | Q2 2024 | |
| $6.33M | 2.20% | 2.21% | Not reported | Q1 2026 | |
| $5.23M | 1.82% | 2.32% | Not reported | Q4 2024 | |
| $5.23M | 1.82% | 0.34% | Not reported | Q1 2024 | |
| Q1 2026Reported May 15, 202620 positions | |||||
| $56.4M | 15.66% | 1.12% | -35.5% | Q2 2024 | |
| $51.2M | 14.21% | 10.45% | Not reported | Q4 2021 | |
| $39.4M | 10.94% | 1.73% | Not reported | Q3 2023 | |
| $25.9M | 7.19% | 11.30% | Not reported | Q4 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $23.1M | 6.41% | 0.38% | Not reported | Q1 2024 |
| $22.5M | 6.26% | 1.22% | Not reported | Q2 2022 | |
| $19.3M | 5.36% | 2.10% | Not reported | Q4 2025 | |
| $18.8M | 5.21% | 3.22% | Not reported | Q2 2024 | |
| $15.8M | 4.38% | 0.75% | Not reported | Q2 2023 | |
| $15.2M | 4.21% | 9.52% | Not reported | Q3 2024 | |
| $13.5M | 3.76% | 1.26% | Not reported | Q2 2024 | |
| $11.3M | 3.13% | 3.37% | Not reported | Q1 2025 | |
| $9.24M | 2.56% | 5.55% | Not reported | Q2 2023 | |
| $8.05M | 2.24% | 0.92% | Not reported | Q2 2023 | |
| $7.14M | 1.98% | 2.49% | Not reported | Q4 2024 | |
| $6.25M | 1.74% | 0.49% | Not reported | Q4 2023 | |
| $6.13M | 1.70% | 2.21% | New | Q1 2026 | |
| $5.95M | 1.65% | 27.56% | Not reported | Q2 2024 | |
| $2.62M | 0.73% | 5.52% | -35.7% | Q3 2021 | |
| $2.51M | 0.70% | 0.34% | Not reported | Q1 2024 | |
| Q4 2025Reported Feb 17, 202621 positions | |||||
| $41.7M | 13.11% | 10.60% | -4.7% | Q4 2021 | |
| $36M | 11.31% | 11.31% | Not reported | Q4 2024 | |
| $27.1M | 8.51% | 1.92% | +9.6% | Q3 2023 | |
| $22.9M | 7.21% | 0.72% | Not reported | Q3 2022 | |
| $22.1M | 6.96% | 1.22% | Not reported | Q2 2022 | |
| $20.1M | 6.32% | 1.90% | Not reported | Q2 2024 | |
| $19.2M | 6.03% | 1.27% | Not reported | Q2 2024 | |
| $16.7M | 5.25% | 2.16% | New | Q4 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $14.5M | 4.57% | 0.39% | -14.7% | Q1 2024 |
| $13.5M | 4.25% | 0.75% | Not reported | Q2 2023 | |
| $12.7M | 3.98% | 3.24% | +18.6% | Q2 2024 | |
| $11.9M | 3.74% | 1.30% | Not reported | Q1 2023 | |
| $10.1M | 3.17% | 9.59% | Not reported | Q3 2024 | |
| $8.76M | 2.75% | 3.96% | +25.0% | Q1 2025 | |
| $8.34M | 2.62% | 0.56% | +54.3% | Q4 2023 | |
| $7.3M | 2.30% | 2.56% | +71.2% | Q4 2024 | |
| $7.27M | 2.29% | 0.92% | Not reported | Q2 2023 | |
| $7.26M | 2.28% | 29.01% | Not reported | Q2 2024 | |
| $5.33M | 1.68% | 5.71% | +705.7% | Q2 2023 | |
| $2.9M | 0.91% | 0.34% | Not reported | Q1 2024 | |
| $2.49M | 0.78% | 68.72% | Not reported | Q3 2021 | |
| Q3 2025Reported Nov 14, 202525 positions | |||||
| $38M | 13.94% | 31.24% | -2.3% | Q2 2024 | |
| $24.7M | 9.04% | 11.14% | -1.2% | Q4 2021 | |
| $19.9M | 7.29% | 1.47% | Not reported | Q2 2022 | |
| $17.6M | 6.45% | 12.52% | +100.5% | Q4 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $16.5M | 6.05% | 0.51% | -18.1% | Q1 2024 |
| $15.9M | 5.82% | 0.90% | Not reported | Q3 2022 | |
| $15.8M | 5.79% | 1.30% | Not reported | Q1 2023 | |
| $15M | 5.48% | 1.51% | Not reported | Q2 2024 | |
| $14.4M | 5.26% | 0.85% | -62.9% | Q3 2023 | |
| $13.1M | 4.81% | 1.76% | Not reported | Q3 2023 | |
| $12.9M | 4.71% | 0.75% | Not reported | Q2 2023 | |
| $11.8M | 4.32% | 1.91% | Not reported | Q2 2024 | |
| $9.01M | 3.30% | 0.80% | Not reported | Q1 2024 | |
| $8.19M | 3.00% | 1.10% | Not reported | Q2 2023 | |
| $8.03M | 2.94% | 2.73% | Not reported | Q2 2024 | |
| $7.19M | 2.63% | 0.45% | Not reported | Q4 2023 | |
| $6.75M | 2.47% | 9.63% | Not reported | Q3 2024 | |
| $3.99M | 1.46% | 3.62% | Not reported | Q1 2025 | |
| $3.48M | 1.27% | 2.07% | Not reported | Q4 2024 | |
| $2.95M | 1.08% | 0.93% | Not reported | Q4 2024 | |
| $2.47M | 0.91% | 0.34% | Not reported | Q1 2024 | |
| ABADVMAdverum Biotechnologies, Inc. | $2.45M | 0.90% | 2.58% | Not reported | Q1 2024 |
| $1.81M | 0.66% | 8.66% | Not reported | Q3 2021 | |
| $740K | 0.27% | 0.68% | Not reported | Q2 2023 | |
| MTMRSNMersana Therapeutics, Inc. | $405K | 0.15% | 1.04% | -96.0% | Q1 2023 |
Premium opens every quarter this fund has filed